SB1 Markets cuts target for Novo Nordisk stock from DKK 370 to DKK 335

Published on 10/27/2026 at 17:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter sales rose 7.00 percent to DKK 78.49 billion. Novo Nordisk stock is EUR 34.78 on October 27, 2026, down 0.09 percent versus the Xetra close.

Analyst view and reporting date

SB1 Markets cut its target from DKK 370 to DKK 335 on October 26, 2026.
Second-quarter adjusted sales rose 7.00 percent to DKK 78.49 billion.
Novo Nordisk stock costs EUR 34.78 at Lang & Schwarz on October 27, 2026 at 5:41 p.m. CEST, 0.09 percent below the Xetra close of October 26, 2026.
Novo Nordisk is scheduled to report third-quarter 2026 results on November 3, 2026.

Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

SB1 Markets cut its price target for Novo Nordisk stock from DKK 370 to DKK 335 and kept its Buy rating on October 26, 2026, according to MarketScreener. The new target is 28.99 percent above the DKK 259.72 home-market price cited on October 27, 2026. At Lang & Schwarz, the stock was trading at EUR 34.78 on October 27, 2026 at 5:41 p.m. CEST, down 0.09 percent versus the Xetra close of October 26, 2026 at EUR 34.81.

Sales growth meets lower margins

Novo Nordisk's second-quarter 2026 adjusted sales rose 7.00 percent at constant exchange rates to DKK 78.49 billion, while adjusted operating profit increased 11.00 percent to DKK 33.39 billion. The figures came with a margin trade-off: adjusted gross margin fell to 78.20 percent from 82.70 percent in the second quarter of 2025. Globenewswire reported the results and the company outlook on August 4, 2026.

What does the target cut signal?

SB1 Markets expects currency-adjusted sales to decline 1.00 percent in 2026, compared with a 3.00 percent consensus decline, and sees 9.00 percent growth in 2028 against a 3.00 percent consensus forecast. Its note also pointed to patent expirations and lower realized prices in the United States as pressure points, while Oral Wegovy remains a growth opportunity. The target change therefore leaves a clear split between operational progress and valuation caution.

November 3 is the next date

Novo Nordisk is scheduled to release third-quarter 2026 results on November 3, 2026, according to the company calendar carried by MarketScreener. The latest company earnings call described adjusted sales growth of 7.00 percent in the second quarter and a 0.00 percent to minus 6.00 percent 2026 adjusted sales outlook at constant exchange rates, as reported by Yahoo Finance on August 5, 2026.

Stock stays near its daily close

The euro quotation sits 0.09 percent below the Xetra close of October 26, 2026. For investors, the November results date will put the 7.00 percent second-quarter sales increase against the company's negative full-year outlook range.

The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.